Vaccine delivery systems using yeast cell wall particles
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11759429-B2
Publication Date
2023-09-19
Expiration Date
Abstract
The present invention generally relates to compositions and methods for delivering a vaccine. The compositions and methods disclosed herein are particularly useful in making prophylactic and therapeutic vaccines.
Core Innovation
The invention describes yeast cell wall particles (YCWPs) used for vaccine delivery, where the YCWP is a hollow, porous structure modified by capping with a silicate. The vaccine includes a viral antigen or bacterial antigen loaded into the yeast cell wall particle, and the disclosed vaccine format excludes a cell of monocytic origin.
The disclosed YCWP vaccine is presented as an anhydrous vaccine prepared by freeze-drying. The partial content describes that the YCWP payload can comprise exogenous biological material including proteins or fragments, nucleic acids, carbohydrates, antigens, and tumor lysate, with the silicate-capping used to retain payload and enhance delivery to mononuclear phagocytes and dermal dendritic cells.
The partial content asserts that silicate capping of YCWPs provides improved retention and reduced leakage compared with uncapped YCWPs, and enhances release into the cytoplasm following delivery. Experimental support in the partial content includes in vivo mouse vaccination using a YCWP loaded with B16 tumor lysate, along with fluorescence-based leaking and cytoplasmic delivery readouts and phagocytosis assessment, where silicate-capped YCWPs show quantitative improvements.
Claims Coverage
The partial content provides two independent claims with three inventive feature groupings for claim 1 and two inventive feature groupings for claim 5.
Silicate-capped hollow porous YCWP vaccine loaded with viral or bacterial antigen
A vaccine comprising a yeast cell wall particle (YCWP) that is a hollow, porous structure, where a viral antigen or bacterial antigen is loaded into the YCWP and the YCWP is modified by capping with a silicate.
Vaccine excludes monocytic-origin cells
The vaccine does not comprise a cell of monocytic origin.
Production of silicate-capped, freeze-dried biological-material-loaded YCWP
A method for producing a yeast cell wall particle loaded with a biological material and capped with a silicate, comprising loading biological material into a yeast cell wall particle, capping the loaded particle with a silicate, and freeze-drying the capped, loaded particle.
Loading scope: protein fragment, nucleic acid, carbohydrate, antigen, and viral or bacterial antigen
The biological material loaded into the yeast cell wall particle comprises a protein or fragment, nucleic acid, carbohydrate, antigen, or combinations thereof, wherein the biological material is viral antigen or bacterial antigen.
Across the independent claims, the inventive focus is on a hollow, porous yeast cell wall particle capped with a silicate, carrying viral or bacterial antigen payloads, excluding monocytic-origin cells, and on a production approach involving loading, silicate capping, and freeze-drying.
Stated Advantages
Improved payload retention compared with uncapped YCWPs.
Reduced leakage compared with uncapped YCWPs.
Greater release into the cytoplasm.
Enhanced delivery associated with silicate-capped YCWPs to mononuclear phagocytes and dermal dendritic cells.
Documented Applications
In vivo mouse vaccination using B16 tumor lysate-loaded YCWPs, including evaluation of improved outcomes/survival with silicate capping.
Fluorescence-based leaking assays demonstrating reduced leaking for silicate-capped YCWPs versus uncapped YCWPs.
Fluorescence-based assays for cytoplasmic delivery demonstrating improved cytoplasmic delivery for silicate-capped YCWPs.
Phagocytosis assays demonstrating quantitative improvements in phagocytosis for silicate-capped YCWPs.
Interested in licensing this patent?